Trust Company of Vermont’s Vertex Pharmaceuticals VRTX Stock Holding History

Trust Company of Vermont’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$179K	Buy	+360	New	+$160K	0.01%	393
2025 Q4	$111K	Buy	245 +14	+6%	+$6.03K	﹤0.01%	441
2025 Q3	$90.5K	Hold	231	–	–	﹤0.01%	468
2025 Q2	$103K	Sell	231 -131	-36%	-$60.4K	﹤0.01%	429
2025 Q1	$176K	Sell	362 -140	-28%	-$65.2K	0.01%	355
2024 Q4	$202K	Buy	502 +106	+27%	+$49.1K	0.01%	348
2024 Q3	$184K	Buy	396 +70	+21%	+$33.6K	0.01%	341
2024 Q2	$153K	Buy	326 +24	+8%	+$10.4K	0.01%	349
2024 Q1	$126K	Sell	302 -45	-13%	-$19K	0.01%	360
2023 Q4	$141K	Sell	347 -12	-3%	-$4.43K	0.01%	321
2023 Q3	$125K	Sell	359 -54	-13%	-$18.9K	0.01%	344
2023 Q2	$145K	Hold	413	–	–	0.01%	349
2023 Q1	$130K	Hold	413	–	–	0.01%	366
2022 Q4	$119K	Buy	413 +300	+265%	+$91.4K	0.01%	360
2022 Q3	$33K	Sell	113 -3	-3%	-$863	﹤0.01%	543
2022 Q2	$33K	Buy	+116	New	+$31K	﹤0.01%	520
2022 Q1	–	Sell	-30	Closed	-$7K	–	734
2021 Q4	$7K	Buy	+30	New	+$5.83K	﹤0.01%	705
2021 Q3	–	Sell	-30	Closed	-$6K	–	708
2021 Q2	$6K	Hold	30	–	–	﹤0.01%	684
2021 Q1	$6K	Hold	30	–	–	﹤0.01%	676
2020 Q4	$7K	Hold	30	–	–	﹤0.01%	667
2020 Q3	$8K	Hold	30	–	–	﹤0.01%	636
2020 Q2	$9K	Hold	30	–	–	﹤0.01%	640
2020 Q1	$7K	Hold	30	–	–	﹤0.01%	716
2019 Q4	$7K	Hold	30	–	–	﹤0.01%	750
2019 Q3	$5K	Hold	30	–	–	﹤0.01%	835
2019 Q2	$6K	Hold	30	–	–	﹤0.01%	822
2019 Q1	$6K	Sell	30 -30	-50%	-$5.54K	﹤0.01%	777
2018 Q4	$10K	Sell	60 -78	-57%	-$13.5K	﹤0.01%	737
2018 Q3	$27K	Hold	138	–	–	﹤0.01%	624
2018 Q2	$23K	Buy	+138	New	+$21.4K	﹤0.01%	675

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Trust Company of Vermont's VRTX Position: Q2 2026 in Review

Trust Company of Vermont opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 360 shares worth $179K. The stake represents 0.01% of the portfolio and ranks #393 among its holdings. This is a return to the name: Trust Company of Vermont previously reported a position in VRTX as recently as Q4 2025.

Trust Company of Vermont first reported a position in VRTX in Q2 2018 and has held it in 30 quarters since. The position peaked at $202K in Q4 2024. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Trust Company of Vermont held 360 shares of Vertex Pharmaceuticals worth $179K as of Q2 2026.
Vertex Pharmaceuticals was a new Trust Company of Vermont position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of Trust Company of Vermont's portfolio in Q2 2026, its #393 holding.
Trust Company of Vermont first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
Trust Company of Vermont's Vertex Pharmaceuticals position peaked at $202K in Q4 2024.
1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trust Company of Vermont's 13F filing for Q2 2026, filed 7 Aug 2026.